XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.20.2

SUPPLEMENTAL CASH FLOW & OTHER DATA | 6 Months Ended
--- | ---
Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract] |
SUPPLEMENTAL CASH FLOW & OTHER DATA | SUPPLEMENTAL CASH FLOW AND OTHER DATA Supplemental cash flow and other data for the three and six months ended June 30, 2020 and 2019 was as follows:
| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
Depreciation expense | $ | 64 |  |  | $ | 56 |  |  | $ | 124 |  |  | $ | 116 |
Amortization expense | 25 |  |  | 25 |  |  | 50 |  |  | 49 |
Depreciation and amortization expense | $ | 89 |  |  | $ | 81 |  |  | $ | 174 |  |  | $ | 165 |
Interest expense | $ | (42) |  |  | $ | (46) |  |  | $ | (84) |  |  | $ | (91) |
Interest income | 1 |  |  | 1 |  |  | 2 |  |  | 2 |
Interest expense, net | $ | (41) |  |  | $ | (45) |  |  | $ | (82) |  |  | $ | (89) |
Interest paid | $ | 55 |  |  | $ | 63 |  |  | $ | 103 |  |  | $ | 91 |
Income taxes paid | $ | 2 |  |  | $ | 80 |  |  | $ | 20 |  |  | $ | 83 |
Accounts payable associated with capital expenditures | $ | 48 |  |  | $ | 15 |  |  | $ | 48 |  |  | $ | 15 |
Dividends payable | $ | 75 |  |  | $ | 72 |  |  | $ | 75 |  |  | $ | 72 |
Businesses acquired: |  |  |  |  |  |  |
Fair value of assets acquired | $ | 120 |  |  | $ | — |  |  | $ | 251 |  |  | $ | 61 |
Fair value of liabilities assumed | — |  |  | — |  |  | (20) |  |  | — |
Fair value of net assets acquired | 120 |  |  | — |  |  | 231 |  |  | 61 |
Merger consideration payable | — |  |  | — |  |  | — |  |  | (5) |
Cash paid for business acquisitions | 120 |  |  | — |  |  | 231 |  |  | 56 |
Less: Cash acquired | — |  |  | — |  |  | 3 |  |  | — |
Business acquisitions, net of cash acquired | $ | 120 |  |  | $ | — |  |  | $ | 228 |  |  | $ | 56 |
Leases: |  |  |  |  |  |  |
Leased assets obtained in exchange for new operating lease liabilities | $ | 47 |  |  | $ | 53 |  |  | $ | 79 |  |  | $ | 78 |
In March 2020, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into law. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of social security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property, and the creation of certain payroll tax credits associated with the retention of employees. The CARES Act also includes a number of benefits that are applicable to the Company and other healthcare providers including, but not limited to, the appropriation of $100 billion to health care providers for related expenses or lost revenues that are attributable to the COVID-19 pandemic. In April 2020, the Company received approximately $65 million from the initial tranche of funds from the government that were distributed to healthcare providers for related expenses or lost revenues that are attributable to the COVID-19 pandemic under the CARES Act. Upon receiving and having satisfied the terms and conditions associated with the distributed funds, which the Company accounts for under a gain contingency model, the Company recognized $65 million of income in other operating income, net for the three and six months ended June 30, 2020. For the six months ended June 30, 2020, net cash provided by operating activities includes the $65 million that the Company received from the initial tranche of funds that were distributed to healthcare providers under the CARES Act. In addition, pursuant to certain rules and regulations promulgated by the U.S. Department of Health and Human Services ("HHS"), the Company applied for additional funds to be distributed by the government under the original $100 billion appropriation to healthcare providers under the CARES Act. As of June 30, 2020, the Company had not yet received approval of its application from HHS for the additional funds requested. As such, the Company's consolidated financial statements as of and for the period ended June 30, 2020 exclude any additional funds that may be distributed by the government for related expenses or lost revenues that are attributable to the COVID-19 pandemic under the CARES Act.

X
- Definition The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -URI http://asc.fasb.org/topic&trid=2134446 + Details
Name: | us-gaap_CashFlowSupplementalDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SupplementalCashFlowElementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration